More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

COVID-19 was the most important development impacting biomanufacturing in 2020. What have been, and what will be, the adjustments required of biopharma companies, CMOs, and suppliers to fortify production capacity and supplies and respond to...

Pfizer and BioNTech have received approval for emergency use of their COVID-19 vaccine from UK regulatory authorities, making it the first COVID-19 vaccine to be approved for emergency use. What is the status of other approval requests and the next...

The COVID-19 pandemic dominated the headlines in 2020 and will again in 2021 as vaccines and treatments move through development, regulatory approval, and distribution. But what have been the other key developments thus far in 2020? How have new...

An upcoming DCAT benchmarking study is examining the lessons learned and risk-mitigation practices taken by bio/pharma companies and suppliers in the wake of the COVID-19 pandemic. What best practices can be applied to mitigate current and future...

Viatris is the new company formed from the combination of Upjohn, Pfizer’s off-patent branded and generic established medicines business, and Mylan. The companies had announced the deal in July 2019, and now that the deal is closed and Viatris is...

It has been 10 years since the Biologics Price Competition and Innovation Act (BPCIA) was signed into law, which authorized the regulatory pathway for biosimilars in the US. Since then, 28 biosimilars have been approved. What are leading products...

A recent DCAT webinar, featuring Graham Lewis, Vice President, Global Pharma Strategy, IQVIA, evaluates the market impact on the COVID-19 pandemic on pharmaceutical industry performance and how fundamentals and growth prospects have been affected....

Solid dosage products are a mainstay, but how are they faring compared to other dosage forms in terms of CDMO growth rates, product mix of new molecular entities approved thus far in 2020, and recent innovative drug approvals? DCAT Value Chain...